GAITHERSBURG, Maryland, and GRAZ, Austria, May 4 /PRNewswire/ -- Expression Pathology Inc. and ORIDIS Biomed GmbH (Graz, Austria) announced today a strategic alliance to offer tissue microproteomic capabilities for protein biomarker discovery and validation. The relationship combines Expression Pathology’s proprietary Liquid Tissue® and DIRECTOR(TM) technologies, which enable mass spectrometry-based discovery and measurement of protein biomarkers in archival tissue, with ORIDIS Biomed’s TISSOMICS(TM) research platform for high-throughput analysis of healthy and diseased patient tissue and its access to formalin-fixed tissue samples associated with longitudinal clinical and pathology information.
